Abstract | BACKGROUND: METHODS: Diabetes was induced by intravenous injection of streptozotozin (60 mg/kg body weight) in 26 male Sprague-Dawley rats. Eight days after diabetes induction, animals were divided into three groups, which were treated with placebo (n=8), SRL (n=9), or CsA (n=9). Six nondiabetic placebo-treated rats were included as controls. RESULTS: CONCLUSION: Compared with CsA, SRL by anti-inflammatory, antifibrotic, and podocyte-protective effects clearly seems to be the superior treatment of prevention or amelioration of diabetic nephropathy in the rat.
|
Authors | Sandra Wittmann, Christoph Daniel, Andrea Stief, Regina Vogelbacher, Kerstin Amann, Christian Hugo |
Journal | Transplantation
(Transplantation)
Vol. 87
Issue 9
Pg. 1290-9
(May 15 2009)
ISSN: 1534-6080 [Electronic] United States |
PMID | 19424027
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- DNA Primers
- Fibronectins
- Immunosuppressive Agents
- Laminin
- RNA, Messenger
- Vascular Endothelial Growth Factor A
- Cyclosporine
- Sirolimus
|
Topics |
- Animals
- Cyclosporine
(therapeutic use)
- DNA Primers
- Diabetes Mellitus, Experimental
(immunology)
- Diabetic Nephropathies
(drug therapy, immunology, pathology, prevention & control)
- Fibronectins
(genetics)
- Immunosuppressive Agents
(therapeutic use)
- Laminin
(genetics)
- Male
- Nephrogenic Fibrosing Dermopathy
(prevention & control)
- Polymerase Chain Reaction
- RNA, Messenger
(drug effects, genetics)
- Rats
- Rats, Sprague-Dawley
- Sirolimus
(therapeutic use)
- Vascular Endothelial Growth Factor A
(genetics)
|